KalVista Pharmaceuticals News

Needham: Reiterates KalVista Pharma (KALV.US) rating and adjusted from buy to buy rating, target price is $35.00.

Zhitong FinanceMay 2 00:21

KalVista Pharma Analyst Ratings

BenzingaMay 2 00:13

Needham Reiterates Buy on KalVista Pharma, Maintains $35 Price Target

BenzingaMay 2 00:14

Needham: Reiterates KalVista Pharma (KALV.US) rating and adjusted from buy to buy rating, target price is $35.00.

Zhitong FinanceApr 11 18:10

KalVista Pharma Analyst Ratings

BenzingaApr 11 18:06

Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), KalVista Pharmaceuticals (KALV) and PTC Therapeutics (PTCT)

TipRanksApr 11 18:00

Buy Rating on KalVista Pharmaceuticals Backed by Sebetralstat's Breakthrough in HAE Treatment

TipRanksMar 12 18:26

KalVista Pharma Analyst Ratings

BenzingaMar 12 03:51

Buy Rating Affirmed for KalVista Pharmaceuticals on Strong Phase 3 Results and Solid Financial Position

TipRanksMar 12 02:45

Buy Rating Reinforced by Strategic CEO Appointment and Promising Drug Development at KalVista Pharmaceuticals

TipRanksMar 11 12:47

Analysts' Top Healthcare Picks: KalVista Pharmaceuticals (KALV), Allakos (ALLK)

TipRanksFeb 27 05:10

HC Wainwright & Co. Maintains Buy on KalVista Pharma, Raises Price Target to $24

BenzingaFeb 14 19:34

Analysts Offer Insights on Healthcare Companies: Rezolute (RZLT) and KalVista Pharmaceuticals (KALV)

TipRanksFeb 14 19:20

Needham Maintains Buy on KalVista Pharma, Raises Price Target to $35

BenzingaFeb 14 03:18

KalVista Pharma Analyst Ratings

BenzingaFeb 14 03:16

Buy Rating and Increased Price Target for KalVista Pharmaceuticals Following Sebetralstat's Clinical Triumphs

TipRanksFeb 14 03:15

Leerink Partners Sticks to Its Buy Rating for KalVista Pharmaceuticals (KALV)

TipRanksFeb 7 21:41

Optimism Intact for KalVista Pharmaceuticals Despite Delay in KONFIDENT Study Data: Outperform Rating Reaffirmed

TipRanksFeb 5 17:36

Positive Outlook for KalVista Pharmaceuticals With Buy Rating Reiterated Ahead of Phase 3 Study Results

TipRanksDec 11, 2023 14:46

Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (BEAM), KalVista Pharmaceuticals (KALV) and Cue Biopharma (CUE)

TipRanksNov 14, 2023 03:10